![]() ![]() ![]() In both groups, we only included patients who had received intravenous vasopressors for at least 12 h after surgery (see Additional file 1: Figure S1). The control group consisted of patients from two observational prospective studies that were done between 20 in the same institution, that included adult patients undergoing cardiac surgery with CPB. In our institution, there is no protocol to guide the use of midodrine and its prescription is at the discretion of the ICU physician. The midodrine group included all consecutive patients having received midodrine within the first week (168 h) after cardiac surgery with CPB, between January 2014 and January 2018 at the 24-bed surgical ICU of the Montreal Heart Institute. Our hypothesis was that midodrine would safely accelerate ICU discharge and be associated with more days free from ICU at 30 days. Other objectives consisted of describing the clinical contexts in which this strategy was used as well as the observed prescription patterns. The main objective of this study was to explore relevant clinical impacts and assess the safety profile of this strategy. In an attempt to hasten weaning of intravenous vasopressors and accelerate ICU discharge after cardiac surgery, intensivists in our center have been increasingly using midodrine in patients with post-CPB vasodilation. The use of midodrine in the context of post-CPB vasodilation represents an interesting approach, given the somewhat predictable temporal pattern of hypotension, relatively short length of stay and availability of hemodynamic monitoring. Most patients in these cohorts presented with hypotension from sepsis and none had undergone cardiac surgery with CPB. Results from small cohort studies suggest that weaning of intravenous vasopressors is accelerated with midodrine administration, without significant side effect, although a recent meta-analysis has not confirmed such results. ![]() Still, its characteristics make midodrine an attractive agent for ICU patients presenting prolonged hypotension attributed to vasodilation who are otherwise stable, and this particular use has been increasingly described in the last few years. Midodrine is an orally administered alpha agonist with predictable hemodynamic effects and an established safety profile outside of the ICU, although its safety for patients with intradialytic hypotension has been questioned. While strategies have emerged to prevent and address post-CPB vasodilation, including refinement of surgical techniques as well as the development of more biocompatible CPB tubing, there is currently no specific treatment postoperatively which would reduce dependence on intravenous vasopressors and length of stay in the ICU. ![]() These patients, besides receiving more intravenous fluid and vasopressors after their surgery, stay longer in the intensive care unit (ICU) and are at increased risk of kidney injury and mortality. This phenomenon is most probably multifactorial, with inflammatory and ischemia–reperfusion insults at the forefront. There was no difference in length of intravenous vasopressors (63 vs 44 hours, p = 0.052), rate of ICU readmission (6 (8.1%) vs 2 (2.7%), p = 0.092) and occurrence of severe kidney injury (11 (14.9%) vs 10 (13.5%) patients, p = 0.462) between groups.ĭepending on the definition used, between 5 and 25% of patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) will present sustained hypotension after surgery presumably attributed to loss of peripheral vascular resistance. A contemporary propensity score matched control group that included patients who presented similarly prolonged hypotension after cardiac surgery was formed.Īfter matching, 74 pairs of patients (1:1) fulfilled inclusion criteria for the study and control groups. We performed a retrospective cohort study that included all consecutive patients having received midodrine while being on vasopressor support in the ICU within the first week after cardiac surgery with CPB, between January 2014 and January 2018 at the Montreal Heart Institute. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |